Xiaosong Jiang

Associate Adjunct Professor

Molecular Biosciences


Education
2001, Peking University Shougang Hospital, China
2007, M.D., Capital University of Medical Sciences, Beijing, China
2009, M.S., Hong Kong University of Science & Technology, Hong Kong, China
2010, Postdoctoral Fellow, University of California Davis, Davis, CA
2012, Ph.D., UC Davis,
Honors and Awards
2008 American Liver Foundation Postdoctoral Research Fellowship
2008 Block Grant, Nutritional Biology, UC Davis
2013 Richard C. Woodward Research Award (Organization: Internal Medicine, UC Davis; Reason for receipt: Based on publications and contribution to the diabetes/metabolic syndrome study; Professional Significance: As a junior faculty member, this award is an encouragement. It expanded my recognition in the department and medical school)
Most Recent Five Book Chapters
2020 Jiang JX^, Török NJ, Barchi JJ : Chapter 7, Galectin-3 Involvement in Fibrotic Diseases, Brenneman J, Iyer MR, (ed), Drug Discovery Series No. 73 Anti-fibrotic Drug Discovery, . 185-210.
2012 Jiang JX^, Chen X, Fukada H, Hsu DK, Liu F, Török NJ: Chapter 23, The Role of Galectin-3 in Stellate Cell Activation and Liver Fibrosis, Klyosov AA, Traber PG, (ed), Galectins and Disease Implications for Targeted Therapeutics, . 391-395.
Research Focus
Liver diseases, pathogenic mechanisms, and cures
Specialty Focus
My research interests are mainly focused on liver diseases including non-alcoholic and alcoholic fatty liver diseases, and autoimmune disorder-related liver injuries. Aiming at finding cures, I have been focused on molecular cellular signaling pathways that related to hepatocyte injury, stellate cell (major fibrotic tissue producers) activation, and inflammatory responses. We recently discovered that Shc, a gene mediates aging progress, is involved in pathogenic signaling in multiple liver diseases and could be potential therapeutic target. Our laboratory has identified a potent Shc inhibitor by screening a library of FDA approved compounds. This compound idebenone has shown significant beneficial effect in several liver diseases models. Meanwhile other small molecules targeting Shc have been generated and currently under evaluation. Other pathogenic signaling in liver metabolism disorders and alcoholic injuries and therapeutic targets are being investigated as well.